Pharmya

  • Home
  • About us
  • Services
    • Pharmacovigilance Systems
    • Operational Pharmacovigilance Activities
    • EU QPPV & Local QPPV services
    • Pharmacovigilance Audits and Training
  • News
  • Careers
  • Contact us
  • English
  • Français
  • Español
You are here: Pharmya > All news
Pharmacovigilance – Questions and answers – Access to medicines not authorised in France for the treatment of serious diseases – ANSM
2023 March Mar 30

Pharmacovigilance – Questions and answers – Access to medicines not authorised in France for the treatment of serious diseases – ANSM

Read more
2022 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission
2023 March Mar 27

2022 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission

Read more
WHO Pharmaceuticals Newsletter
2023 March Mar 23

WHO Pharmaceuticals Newsletter

Read more
Standing Scientific Committee on Surveillance and Pharmacovigilance – Restricted Expertise Session of 15 November 2022 minutes
2023 March Mar 20

Standing Scientific Committee on Surveillance and Pharmacovigilance – Restricted Expertise Session of 15 November 2022 minutes

Read more
Guideline on computerised systems and electronic data in clinical trials
2023 March Mar 17

Guideline on computerised systems and electronic data in clinical trials

Read more
EU-PRAC recommendations on signals adopted at the 6-9 February 2023 meeting
2023 March Mar 13

EU-PRAC recommendations on signals adopted at the 6-9 February 2023 meeting

Read more
Welcome to the team!
2023 March Mar 09

Welcome to the team!

The Pharmya team is growing! A big welcome to Angélique, our new team assistant!

Read more
Letter to QPPVs – International Transfer of ICSRs from EV and GDPR
2023 March Mar 06

Letter to QPPVs – International Transfer of ICSRs from EV and GDPR

Read more
Questions and answers – Clinical Trials Information System (CTIS) and Clinical Trials Regulation (CTR)
2023 March Mar 03

Questions and answers – Clinical Trials Information System (CTIS) and Clinical Trials Regulation (CTR)

Read more
List of medicines under additional monitoring
2023 February Feb 27

List of medicines under additional monitoring

https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/medicines-under-additional-monitoring/list-medicines-under-additional-monitoring

Read more
  • « Previous

Pharmya – Pharmacovigilance

PHARMYA is a French based company, dedicated to providing Pharmacovigilance services. Its mission is to support the pharmaceutical industry, biotechnology companies, research centers and their service providers in their efforts to comply with international Pharmacovigilance regulations.

Contact

  • PHARMYA
  • 315 Av. Saint Sauveur du Pin
  • 34980 Saint Clément de Rivière (Montpellier), France
  • Phone: +33 411 93 21 10
  • Email: info@pharmya.com
  • Website: www.pharmya.com

News

  • Pharmacovigilance – Questions and answers – Access to medicines not authorised in France for the treatment of serious diseases – ANSM
  • 2022 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission
  • WHO Pharmaceuticals Newsletter
Copyright © 2018 - Pharmya - Legal terms - Quality Policy